TICKER INTELLIGENCE
NYSE/NASDAQ: CAH
4
Active Bills
1
Gov't Contracts
31
Congressional Trades
Cardinal Health is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 5 active Congressional signals mentioning Cardinal Health, including 4 bills and 1 federal contract. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
⚠ ⚠️ PRESIDENTIAL ACTION: Presidential Memorandum signed 7/30/2026: "Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended". This DPA action will boost investment and production in domestic critical mineral recycling and processing, likely increasing stock valuations for pure-play recovery companies and defense contractors reliant on secure rare-earth magnet supplies, while potentially raising costs for import-dependent manufacturers.
⚠ System: No suspicious timing patterns detected
⚠ Marjorie Taylor Greene bought $1,001 - $15,000 in HD (Home Depot, Inc.) on 2025-10-24, 27 days before the introduction of HR6217 ("Revitalize Our Neighborhoods Act of 2025"), a bill that could increase demand for construction and renovation services.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Marjorie Taylor Greene bought $1,001 - $15,000 in LLY on 2025-05-14, 5 days before the DeOndra Dixon INCLUDE Project Act of 2025 (HR3491) was introduced and referred to the Committee on Energy and Commerce.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Greene bought $1K-$15K in MSFT on Sept 20, 2024 — 25 days after Deloitte & Touche secured a $66.8M VA cybersecurity contract. Microsoft is a major partner for Deloitte in federal IT, but the trade is small and the signal is neutral, making the timing a mild coincidence.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No valid trades to analyze
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
HR4581 (340B PATIENTS Act) is an early-stage bill that codifies existing contract pharmacy access within the 340B drug discount program. It creates no new spending, mandates, or regulatory changes. With only a July 2025 referral to committee and no subsequent action, it has zero near-term market impact. CVS has rallied 16.51% over 30 days to $83.68, but this bill is not a driver of that movement.
The SUPPORT for Patients and Communities Reauthorization Act (P.L. 119-44) became law on December 1, 2025, extending federal substance use disorder and mental health funding through FY2030. This creates a structural tailwind for diagnostic testing (LH, DGX) and pharmaceutical distribution (CAH) via sustained grant programs, while also providing a positive policy backdrop for psychedelic therapy developers (CMPS, MNMD). Recent market data shows diagnostic stocks declining over the past 30 days, with LH at $261.79 (-1.88% 30d) and DGX at $193.52 (-1.26% 30d), suggesting the market has not yet priced in this long-term authorization catalyst.
→ Extended federal grant funding for SUD treatment programs increases the number of funded treatment slots and medication-assisted treatment (MAT) patients, driving incremental pharmaceutical distribution volume.
HR7877 (Shane DiGiovanna Act) mandates a 2-year nationwide Medicaid demonstration program covering wound care and OTC drugs for epidermolysis bullosa. The bill is in early legislative stages (referred to committee, 5 cosponsors) with no explicit funding authorized. Market impact is minimal — the affected patient population is small (~3,000-5,000 individuals), and near-term passage is uncertain.
HR1970 (Providing Veterans Essential Medications Act) is in early legislative stages, having been referred to the House Veterans' Affairs subcommittee. The bill mandates VA reimbursement for high-cost medications dispensed to veterans in State nursing homes, but authorizes no specific funding and remains months from passage. Real market data shows CVS up 16% in 30 days while CAH is down 10%, reflecting broader distribution-sector dynamics rather than this early-stage bill.
→ Cardinal Health, as a pharmaceutical distributor serving long-term care and institutional pharmacies, benefits from predictable federal payment for high-cost veteran medications distributed through State homes, reducing credit risk and stabilizing volume for its specialty distribution business.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →